Companies › MapLight Therapeutics
2 active drug programs in 3 registered trials: 3 Phase 2; Psychiatry, Neurology; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ML-004 | – | Phase 2 | Autism Spectrum Disorder | Nov 2027 |
| ML-007C-MA | – | Phase 2 | Psychosis Associated With Alzheimer's Disease; Schizophrenia | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05889273 | ML-004 | Phase 2 | Autism Spectrum Disorder | Psychiatry | Nov 2027 |
| NCT06887192 | ML-007C-MA | Phase 2 | Psychosis Associated With Alzheimer's Disease | Neurology | Dec 2027 |
| NCT07459647 | ML-007C-MA | Phase 2 | Schizophrenia | Psychiatry | Feb 2030 |
Cash and short-term investments of $305m on 2026-06-30; operating cash outflow about $195m a year; runway about 19 months at that burn, to Jan 2028; 2 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Spinogenix Shanghai Auzone Biological Technology Reviva Pharmaceuticals Noema Pharma Bazelet Nehushtan
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.